openPR Logo
Press release

Lipid Nanoparticles, Key Component of COVID-19 mRNA Vaccines

Lipid Nanoparticles, Key Component of COVID-19 mRNA Vaccines

Lipid nanoparticles have been developed as vehicles for small molecule delivery by the nanomedicine and materials communities and are now a key component of COVID-19 mRNA vaccines.

Vaccines against COVID-19 have been developed with unprecedented speed. In particular, mRNA vaccines — a technology already in clinical trials for other infectious diseases, such as influenza — have shown impressive efficacy in clinical trials. 

mRNA vaccines rely on the delivery of mRNA into the cytoplasm of host cells, where it can be transcribed into antigenic proteins to trigger the production of neutralizing antibodies. However, mRNA is three to four orders of magnitude larger than molecules that readily diffuse into cells; in addition, the dense negative charge of mRNA electrostatically repulses the anionic cell membrane, preventing its uptake. Therefore, mRNA vaccines require a delivery vehicle that not only protects the nucleic acid from degradation but allows the mRNA to get into cells.

BioNTech/Pfizer’s and Moderna’s mRNA vaccines both use lipid nanoparticles as mRNA carriers. The impressive speed at which these vaccines could be developed is partly owed to the fact that nucleic acid delivery by lipid nanoparticles has long been investigated and optimized by the nanomedicine community, who thoroughly studied lipid nanoparticle chemistry, structure, surface, injection routes, uptake, endosomal escape, cargo release, dosage, clearance and, importantly, safety.

Owing to their size and properties, lipid nanoparticles are taken up by cells via endocytosis, and the ionizability of the lipids at low pH (likely) enables endosomal escape, which allows release of the cargo into the cytoplasm. In addition, lipid nanoparticles usually contain a helper lipid to promote cell binding, cholesterol to fill the gaps between the lipids, and a polyethylene glycol (PEG) to reduce opsonization by serum proteins and reticuloendothelial clearance. The relative amounts of ionizable lipid, helper lipid, cholesterol and PEG substantially affect the efficacy of lipid nanoparticles, and need to be optimized for a given application and administration route.

It was a long road to optimizing lipid nanoparticle formulations for nucleic acid delivery. To achieve clinical efficacy, every aspect of the lipid nanoparticle formulation had to be optimized, and more than 300 ionizable lipids had to be screened. Furthermore, all key steps of the lipid nanoparticle journey in the body had to be understood before clinical trials could begin. This knowledge has certainly contributed to the rapid development of COVID-19 mRNA vaccines.

From a materials science perspective, the success of lipid nanoparticle mRNA vaccines is exciting and important, as it underlines the value of materials science for medical advances and motivates further fundamental and applied nanoparticle research, which will hopefully be reflected in future funding cycles. 

Huateng Pharma, a professional PEG supplier, is dedicated to manufacturing and supplying a wide range of PEG derivatives. Lipid nanoparticles is a key component of COVID-19 mRNA vaccines. We can supply below PEG products which are excipients used in COVID-2019 vaccine.

1.ALC-0159, mPEG-N,N-Ditetradecylacetamide, CAS No. 1849616-42-7
2.mPEG-DMG, CAS NO. 160743-62-4 
5.mPEG-OH, CAS NO. 9004-74-4

Hunan Huateng Pharmaceutical Co. Ltd.
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

Human Huateng Pharmaceutical Co., Ltd. is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on.
Huateng Pharma is committed to providing cost-effective pharmaceutical products and services to customers around the world with the belief of “Strive for the Human Health".

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lipid Nanoparticles, Key Component of COVID-19 mRNA Vaccines here

News-ID: 2299103 • Views: 818

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases

More Releases for PEG

Biopharma PEG Provides Monodisperse PEGs In Drug Development
Monodisperse PEG products usually are organic compounds with a molecular weight of less than 1000. Monodispersed PEG linkers are pure compounds with a single molecular weight. Monodisperse polyethylene glycol(PEG) molecular weight is fixed. It can not be obtained by polymerization. It must be by the appropriate reaction of the basic polyethylene glycol fragment. With advancements in both synthetic and purification chemistry over the past two decades, monodispersed PEG linkers have become more commercially
High Quality PEG Raw Materials From Biopharma PEG
Polyethylene glycol (PEG) is a polyether compound derived from petroleum with many applications, from industrial manufacturing to medicine. PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE), it has wide variety of applications depending on the length of the polymer chain and the molecular weight of the final polymer. The synthesis of PEG is done by polymerizing ethylene oxide, the main ingredient in antifreeze, using a ring-opening
Polyethylene Glycol (PEG) in Medical Market 2021 | Detailed Report
ReportsnReports publishes the report titled Polyethylene Glycol (PEG) in Medical that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital
PEG-3 Distearate Market global outlook and forecast 2021 -2027
The Global PEG-3 Distearate Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a PEG-3 Distearate makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements. The report likewise spins around
The Advantages of Monodisperse PEG In Drug Development?
Monodisperse PEG products usually are organic compounds with a molecular weight of less than 1000. Monodispersed PEG linkers are pure compounds with a single molecular weight. In contrast, polydisperse PEGs linkers contain variations in molecular weight with an average molecular weight. The use of polydisperse PEGs linkers in drug development has led to problems in biological applications due to steric hindrance and binding. With advancements in both synthetic and purification chemistry over the
Application of PEG In Click Chemistry
Polyethylene glycol (PEG) is a biocompatible, synthetic, hydrophilic polyether compound that has many applications, mostly in the medical industry, but also in the chemical and industrial sectors. The synthesis of PEG is done by polymerizing ethylene oxide, the main ingredient in antifreeze, using a ring-opening technique, which allows for PEGs of a range of molecular weights and molecular weight distributions to be constructed. This range in weights is what makes